卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)重組蛋白
Recombinant Lecithin Cholesterol Acyltransferase (LCAT)
phosphatidylcholine-sterol O-acyltransferase; Phospholipid-cholesterol acyltransferase
- 編號(hào)URPJ516Hu01
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 來源原核表達(dá)
- 宿主E.coli
- 內(nèi)毒素水平<1.0EU/µg(LAL法測(cè)定)
- 亞細(xì)胞定位分泌
- 預(yù)測(cè)分子量17.4kDa
- 實(shí)際分子量18kDa(差異分析請(qǐng)參閱說明書)
- 片段與標(biāo)簽Ile290~Ser433 with N-terminal His Tag
- 緩沖液成份磷酸鹽緩沖液（pH7.4，含有 0.01% SKL, 1mM DTT, 5% Trehalose和Proclin300.）
- 性狀凍干粉
- 純度> 90%
- 等電點(diǎn)5.8
-
應(yīng)用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，請(qǐng)參見活性蛋白。 - 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價(jià)格 ¥ 542 ¥ 1356 ¥ 2712 ¥ 8136 ¥ 20340
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
Figure. Gene Sequencing (Extract)
-
SDS-PAGE圖
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
序列
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲(chǔ)存
避免反復(fù)凍融。2-8°C不超過一個(gè)月，-80°C不超過12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPJ516Hu01 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPJ516Hu02 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UAPJ516Hu01 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)活性蛋白 | Cell?culture;?Activity?Assays. |
| UPAJ516Hu01 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)多克隆抗體 | WB; IHC; ICC; IP. |
| UPAJ516Hu02 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)多克隆抗體 | IHC |
| ULAJ516Hu71 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| UMAJ516Hu21 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)單克隆抗體 | WB; IHC |
| UMAJ516Hu25 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)單克隆抗體 | IHC |
| UMAJ516Hu27 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)單克隆抗體 | IHC |
| UMAJ516Hu29 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)單克隆抗體 | WB |
| UMAJ516Hu24 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)單克隆抗體 | IHC; ICC/IF |
| UMAJ516Hu26 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)單克隆抗體 | WB |
| UMAJ516Hu28 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)單克隆抗體 | WB |
| UMAJ516Hu22 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)單克隆抗體 | WB; IHC |
| UMAJ516Hu23 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)單克隆抗體 | WB |
| USEJ516Hu | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| USCJ516Hu | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| ULMJ516Hu | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Int J Rheum Dis | Plasma phospholipase, γ‐CEHC and antioxidant capacity in fibromyalgia [PubMed: 26585319] |
| Inflammation. | Alteration?of?Lysophosphatidylcholine-Related?Metabolic?Parameters?in the?Plasma?of?Mice?withExperimental?Sepsis. [pubmed:28028754] |
| British journal of cancer | A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours. [pubmed:28664912] |
| Journal?of?Agricultural?and?Food?Chemistry | Lipid-lowering effects of medium-chain triglyceride-enriched coconut oil in combination with licorice extracts in experimental hyperlipidemic mice [Pubmed: 30244576] |
| Experimental and Therapeutic Medicine | Identification and validation of differentially expressed proteins in serum of CSU patients with different duration of wheals using an iTRAQ labeling, 2D?LC?MS/MS [Doi: 10.3892/etm.2018.6818] |
| British Journal of Cancer | Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel. [Pubmed: 31388184] |
| BIOMEDICINE & PHARMACOTHERAPY | The synergistic mechanism of total saponins and flavonoids in Notoginseng? Safflower pair against myocardial ischemia uncovered by an integrated?… [Pubmed: 32739736] |
| Biomedicine & Pharmacotherapy | Pharmacokinetics/pharmacometabolomics-pharmacodynamics reveals the synergistic mechanism of a multicomponent herbal formula, Baoyuan decoction??- [] |
| Cell Metab | Defects in a liver-bone axis contribute to hepatic osteodystrophy disease progression [Pubmed:35235775] |
留言咨詢
